Commercialization of fermented lactoferrin takes a major step forward

Novonesis Group has signed an agreement with TurtleTree—an expert in precision-fermented ingredients and the first to receive a US GRAS “No Objection Letter” for its fermented lactoferrin LF+—to advance commercialization of fermented lactoferrin. Novonesis is also making a minor investment in TurtleTree, joined by 321Catalyst Ventures, the corporate venture arm of Mitsui Chemicals.

Which applications do you think will benefit first from precision‑fermented lactoferrin—infant nutrition, sports and wellness, or broader functional foods—and why?